BioPharmSignal logoBioPharmSignal

Biotech News

Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)

Paratek Pharmaceuticals (PRTK)Paratek PharmaceuticalsCommercial

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10 million patient market

Acquisition advances Paratek's vision to become a multi-product company focused on...

Related news

PRTKParatek Pharmaceuticals2026-03-18 07:00 EST

Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform

PRTKParatek Pharmaceuticals2023-09-07 15:34 EST

Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings

View all latest news

Paratek Pharmaceuticals

Paratek Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

PRTKParatek Pharmaceuticals2026-04-16 07:30 EST

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026

PRTKParatek Pharmaceuticals2026-03-18 07:00 EST

Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform

PRTKParatek Pharmaceuticals2026-02-24 07:30 EST

Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract

PRTKParatek Pharmaceuticals2025-10-17 07:30 EST

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025

PRTKParatek Pharmaceuticals2025-05-21 08:26 EST

Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States